175 related articles for article (PubMed ID: 29232033)
1. Amyopathic dermatomyositis with anti-TIF1 gamma antibodies.
Schiffmann ML; Warneke VS; Ehrchen J
J Dtsch Dermatol Ges; 2018 Jan; 16(1):76-78. PubMed ID: 29232033
[No Abstract] [Full Text] [Related]
2. Dermatomyositis with anti-TIF1-γ antibodies.
De Greef A; Marot L; Yildiz H; Baeck M
BMJ Case Rep; 2018 Oct; 2018():. PubMed ID: 30297488
[No Abstract] [Full Text] [Related]
3. A novel case of TIF1 gamma autoantibody positive dermatomyositis associated with a non-functional pancreatic neuroendocrine tumor.
Varedi D; Frigerio A; Scaife C; Hull C
Dermatol Online J; 2019 Mar; 25(3):. PubMed ID: 30982303
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
[TBL] [Abstract][Full Text] [Related]
5. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
Muro Y; Ishikawa A; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
[TBL] [Abstract][Full Text] [Related]
6. Necrotic ulcerations in dermatomyositis: a marker of bad prognosis?
Borghi A; Corazza M; Mantovani L; Ricci M; Maranini C; Virgili A
G Ital Dermatol Venereol; 2016 Jun; 151(3):318-9. PubMed ID: 27176089
[No Abstract] [Full Text] [Related]
7. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-γ.
Matsuura E; Ishiguro N; Katsumata Y; Urano W; Yamanaka H; Kondo M; Kuwana M; Kaji K; Hamaguchi Y; Fujimoto M; Kawashima M
Eur J Dermatol; 2012; 22(5):668-71. PubMed ID: 22992252
[TBL] [Abstract][Full Text] [Related]
8. Case report of anti-transcription intermediary factor-1-γ/α antibody-positive dermatomyositis associated with gastric cancer and immunoglobulin G4-positive pulmonary inflammatory pseudotumor.
Ito K; Imafuku S; Hamaguchi Y; Fujimoto M; Nakayama J
J Dermatol; 2013 Jul; 40(7):567-9. PubMed ID: 23663102
[TBL] [Abstract][Full Text] [Related]
9. Dysphagia as a presenting symptom in a case of dermatomyositis and occult gastric malignancy.
Dhungel S; Chalise SN; Kandel S; Shrestha B; Paudel B
Nepal Med Coll J; 2005 Jun; 7(1):77-8. PubMed ID: 16295730
[TBL] [Abstract][Full Text] [Related]
10. Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis.
Venalis P; Selickaja S; Lundberg K; Rugiene R; Lundberg IE
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):648-651. PubMed ID: 28704599
[TBL] [Abstract][Full Text] [Related]
11. Amyopathic and anti-TIF1 gamma-positive dermatomyositis: analysis of a monocentric cohort and proposal to update diagnostic criteria.
Didona D; Juratli HA; Scarsella L; Keber U; Eming R; Hertl M
Eur J Dermatol; 2020 Jun; 30(3):279-288. PubMed ID: 32666928
[TBL] [Abstract][Full Text] [Related]
12. Amyopathic dermatomyositis resembling stasis dermatitis.
Seidler AM; Wasserman DI; González-Serva A; Konnikov N
J Am Acad Dermatol; 2008 Sep; 59(3):515-8. PubMed ID: 18571770
[TBL] [Abstract][Full Text] [Related]
13. TIF1γ-overexpressing, highly progressive endometrial carcinoma in a patient with dermato-myositis positive for malignancy-associated anti-p155/140 autoantibody.
Kasuya A; Hamaguchi Y; Fujimoto M; Tokura Y
Acta Derm Venereol; 2013 Nov; 93(6):715-6. PubMed ID: 23407650
[No Abstract] [Full Text] [Related]
14. Anti-transcriptional intermediary factor 1-γ antibody as a biomarker in patients with dermatomyositis.
Shimizu K; Kobayashi T; Kano M; Hamaguchi Y; Takehara K; Matsushita T
J Dermatol; 2020 Jan; 47(1):64-68. PubMed ID: 31638280
[TBL] [Abstract][Full Text] [Related]
15. Anti-p155/140 antibody-positive dermatomyositis with metastasis originating from an unknown site.
Ohashi M; Shu E; Tokuzumi M; Fujioka K; Ishizuka T; Hara A; Fujimoto M; Kaji K; Seishima M
Acta Derm Venereol; 2011 Jan; 91(1):84-5. PubMed ID: 21088812
[No Abstract] [Full Text] [Related]
16. Clinically amyopathic dermatomyositis in a patient with an extramedullary plasmacytoma of the tongue.
Orme CM; Zhou LH; Lazic T
J Dermatol; 2012 Jul; 39(7):656-7. PubMed ID: 22211639
[No Abstract] [Full Text] [Related]
17. Anti-TIF1-γ autoantibodies-positive dermatomyositis: where is the malignancy?
Zachou A; Zouvelou V; Papadimas GK; Rentzos M; Papadopoulos C
Rheumatology (Oxford); 2018 Apr; 57(4):756. PubMed ID: 28968891
[No Abstract] [Full Text] [Related]
18. Amyopathic dermatomyositis.
Olsen NJ; Park JH; King LE
Curr Rheumatol Rep; 2001 Aug; 3(4):346-51. PubMed ID: 11470054
[TBL] [Abstract][Full Text] [Related]
19. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.
Merlo G; Clapasson A; Cozzani E; Sanna L; Pesce G; Bagnasco M; Burlando M; Parodi A
Arch Dermatol Res; 2017 Mar; 309(2):87-95. PubMed ID: 27928683
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in dermatomyositis-specific autoantibodies.
Fujimoto M; Watanabe R; Ishitsuka Y; Okiyama N
Curr Opin Rheumatol; 2016 Nov; 28(6):636-44. PubMed ID: 27533321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
